Rani Therapeutics (RANI) Expected to Release Earnings on Thursday

Rani Therapeutics (NASDAQ:RANI – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rani Therapeutics to announce earnings of ($0.05) per share and revenue of $1.28 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $0.93 million. On average, analysts expect Rani Therapeutics to post ($0.17) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Rani Therapeutics Trading Up 0.7%

NASDAQ RANI opened at $0.56 on Wednesday. The stock’s 50 day moving average is $0.76 and its 200 day moving average is $0.93. Rani Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.63. The stock has a market cap of $77.48 million, a PE ratio of -2.06 and a beta of 0.61.

Analysts Set New Price Targets

A number of brokerages have issued reports on RANI. Weiss Ratings raised shares of Rani Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Chardan Capital reissued a “buy” rating on shares of Rani Therapeutics in a report on Thursday, October 22nd. Finally, HC Wainwright reissued a “buy” rating on shares of Rani Therapeutics in a report on Tuesday, October 6th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rani Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.33.

Get Our Latest Stock Report on RANI

About Rani Therapeutics

(Get Free Report)

Rani Therapeutics Holdings, Inc is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion.

The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.

Read More

Earnings History for Rani Therapeutics (NASDAQ:RANI)

Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.